4Vote!
Market Wire (Free subscription) | 11/16/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Comcast Corporation (NASDAQ: CMCSK), Century Aluminum Co. (NASDAQ: CENX), Susquehanna Bancshares Inc. (NASDAQ: SUSQ), Vertex...
4Vote!
Business Wire (Free subscription) | 11/12/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST. The presentation will be webcast live and may be accessed from ‘Events & Presentations’ on the home page of Vertex’s website at...
4Vote!
Business Wire (Free subscription) | 11/10/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued interest for approximately 4.8 million shares of the Company’s common stock, which is approximately 140,000 shares...
4Vote!
PR News Wire (Free subscription) | 11/09/2009
BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.
4Vote!
Market Wire (Free subscription) | 11/03/2009
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), Bank of America Corp. (NYSE: BAC), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Johnson & Johnson (NYSE: JNJ).
4Vote!
Stock Market Analysis (Free subscription) | 11/02/2009
Today, November 2, 2009, there are several stock gainers that are breaking out with some nice momentum. If you are looking to day trade today, you might want to check out the following stocks. Check out some of today's biggest gainers and the Top Stocks for 2009 . You can find my Past, Current, and Future Stock Gainers Report Right Here Top Stocks 11/2/09 - Biggest Gainers Today Discuss Stocks - www.stockstobuy.org...
4Vote!
Stock Market Analysis (Free subscription) | 11/02/2009
Below is a list of some of the largest stock gainers and losers so far in pre market for November 2, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 11/2/09 Human Genome Sciences Inc. (HGSI) - Positive Lupus Drug Trial Data Adeona Pharmaceuticals, Inc. (AEN) - IRB Approval Terra Industries Inc. (TRA) - CF Industries boosts cash portion of Terra offer Kopin...
4Vote!
Business Wire (Free subscription) | 10/31/2009
BOSTON--(BUSINESS WIRE)--More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX). The data from Study C208 will be presented in an oral presidential plenary session at the...
4Vote!
Business Wire (Free subscription) | 10/28/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that treatment with telaprevir-based regimens in Study 107 resulted in high sustained viral response (SVR) rates in treatment-failure patients infected with hepatitis C virus (HCV). Interim results from 94 patients in Study 107 showed that 90% of prior treatment relapsers (n=29) and 55% of prior treatment...
4Vote!
Business Wire (Free subscription) | 10/26/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reviewed recent business and clinical progress and reported consolidated financial results for the quarter ended September 30, 2009. “Vertex has made significant advancements across its business and expects to enter 2010 in a strong financial position that will enable the continued investment in late-stage...
5Vote!
Cara Community - Comments (Free subscription) | 10/15/2009
In reply to Cara's Commentary & Community Chat, Thursday, Oct. 15, 2009 : Rating Company Name Symbol 1.0 Ryanair Holdings plc RYAAY 1.4 Stericycle, Inc. SRCL 1.5 Activision Blizzard, Inc ATVI 1.6 Teva Pharmaceutical Industries Limited TEVA 1.6 Warner Chilcott plc WCRX 1.7 Cognizant Technology Solutions Corp CTSH 1.7 Express Scripts, Inc. ESRX 1.7 Gilead Sciences, Inc. GILD 1.8 Foster Wheeler AG....
Explore : Aerospace and Defense,
Altera Corporation,
Apollo Group,
Automatic Data Processing,
Baidu,
Biotechnologies,
Business,
Cable TV Networks industry,
Celgene Corporation,
Cisco Systems,
Cognizant Technology Solutions Corp.,
Comcast Corporation,
Computer industry,
Construction,
Costco Wholesale Corporation,
DENTSPLY International Inc.,
Discount Stores,
Drug Manufacturers,
Education,
Foster Wheeler AG,
Genzyme,
Health Industries,
Intel Corp.,
KLA-Tencor Corporation,
LAM Research Corporation,
Media,
Medical Equipment,
Microsoft Corporation,
Microsoft Yahoo,
Network Equipment,
Oracle Corporation,
Research in Motion Ltd.,
Retailers,
Ryanair Holdings plc,
Seagate Technology,
Search Engines,
Semi Conductors,
Software industry,
Starbucks Corporation,
Storage,
Symantec Corporation,
Technology,
Telecommunication,
Telecommunication Companies
4Vote!
Business Wire (Free subscription) | 10/14/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT. The conference call will be webcast live and may be accessed from the ‘Events & Presentations’ page of Vertex’s website...
5Vote!
iStockAnalyst.com (Free subscription) | 10/01/2009
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) sold the rights to its key milestone payments for their hepatitis C drug in development telaprevir, worth up to $95 million. [More...]
Videos